Table 3 Treatments and prognosis
From: Vogt-Koyanagi-Harada disease: a retrospective and multicentric study of 41 patients
Characteristics | All patients n/N (%) - Means | Patients diagnosed at the early stage n/N (%) - Means | Patients diagnosed at the chronic stage n/N (%) - Means | p |
|---|---|---|---|---|
Treatment with corticotherapy: | ||||
- Bolus | 34/41 (83) | 26/31 (84) | 5/10 (50) | < 0.01 |
- Mean posology of bolus (mg/day) | 730 | 650 | 550 | < 0.01 |
- Oral corticotherapy at 1 mg/kg | 37/41 (90) | 26/31 (84) | 8/10 (80) | |
Associated treatments (first line or relapse): | ||||
- Immunosuppressive agents: | 12/41 (29) | 5/31 (16) | 6/10 (60) | < 0.01 |
Azathioprine | 7/41 (17) | |||
Ciclosporine | 1/41 (2) | |||
Mycophenolate mofetil | 3/41 (7) | |||
- Biological therapies (infliximab and adalimumab) | 5/42 (12) | 3/31 (10) | 2/10 (20) | < 0.01 |
Clinical relapse | 18/41 (44) | 11/31 (35) | 7/10 (70) | 0.15 |
Mean duration of follow-up after treatment (months) | 13.3 [1–140] | 30.9 | 44.1 | |
Mean posology of corticotherapy at relapse (mg) | 15 | 18.6 | 4.6 | |
Mean duration of treatment (months) | 23.4 | 20 | 36 | < 0.01 |
Final visual acuity (/10): | ||||
- Right eye | 8.6 | 8.8 | 7.7 | 0.7 |
- Left eye | 8.8 | 8.6 | 8.7 | 0.9 |
Complications: | ||||
- Cataract | 7/41 (17) | 4/31 (13) | 3/10 (30) | < 0.01 |
- Glaucoma | 2/41 (5) | 1/31 (3) | 1/10 (10) | < 0.01 |